Recycling tenofovir in second-line antiretroviral treatment with dolutegravir: outcomes and viral load trajectories to 72 weeks

BACKGROUND: Recycling tenofovir and lamivudine/emtricitabine with dolutegravir (TLD) after failure of non-nucleoside transcriptase inhibitor (NNRTI) first-line antiretroviral therapy (ART) is more tolerable and scalable than dolutegravir plus optimized nucleoside reverse transcriptase inhibitors. St...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:J Acquir Immune Defic Syndr
Huvudupphovsmän: Keene, Claire M, Cassidy, Tali, Zhao, Ying, Griesel, Rulan, Jackson, Amanda, Sayed, Kaneez, Omar, Zaayid, Hill, Andrew, Ngwenya, Olina, van Zyl, Gert, Flowers, Tracy, Goemaere, Eric, Maartens, Gary, Meintjes, Graeme
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2023
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7614301/
https://ncbi.nlm.nih.gov/pubmed/36706364
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAI.0000000000003157
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk